Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Organogenesis Holdings (ORGO) Equity Average (2016 - 2026)

Organogenesis Holdings has reported Equity Average over the past 10 years, most recently at $277.6 million for Q4 2025.

  • For Q4 2025, Equity Average rose 2.55% year-over-year to $277.6 million; the TTM value through Dec 2025 reached $277.6 million, up 2.55%, while the annual FY2025 figure was $281.5 million, 3.96% up from the prior year.
  • Equity Average for Q4 2025 was $277.6 million at Organogenesis Holdings, up from $244.2 million in the prior quarter.
  • Over five years, Equity Average peaked at $278.3 million in Q1 2024 and troughed at $147.4 million in Q1 2021.
  • A 5-year average of $245.1 million and a median of $258.2 million in 2022 define the central range for Equity Average.
  • Biggest five-year swings in Equity Average: soared 354.28% in 2021 and later dropped 12.07% in 2025.
  • Year by year, Equity Average stood at $215.3 million in 2021, then grew by 21.25% to $261.0 million in 2022, then increased by 6.42% to $277.8 million in 2023, then dropped by 2.54% to $270.7 million in 2024, then grew by 2.55% to $277.6 million in 2025.
  • Business Quant data shows Equity Average for ORGO at $277.6 million in Q4 2025, $244.2 million in Q3 2025, and $238.1 million in Q2 2025.